Corbus Pharmaceuticals Holdings (CRBP) Income from Continuing Operations (2013 - 2025)
Corbus Pharmaceuticals Holdings' (CRBP) quarterly Income from Continuing Operations came in at 24417000.0 in Q3 2025, down 34.86% year-on-year from 37485778.43 in Q3 2024, and down 1958.22% quarter-over-quarter from 1314000.0 in Q2 2025.
Corbus Pharmaceuticals Holdings (CRBP) Income from Continuing Operations (2013 - 2025) Analysis & Trends
Corbus Pharmaceuticals Holdings' Income from Continuing Operations history runs 13 years deep, the most recent figure standing at 24417000.0 for Q3 2025.
- On a quarterly basis, Income from Continuing Operations fell 34.86% year-over-year to 24417000.0 in Q3 2025; TTM through Sep 2025 was 22610000.0, a 56.35% increase from a year earlier, with the FY2024 full-year figure at 3493000.0, up 102.49% from the prior year.
- Income from Continuing Operations slipped to 24417000.0 in Q3 2025 per CRBP's latest filing, from 1314000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 1852000.0 in Q4 2024 and bottomed at 53964679.0 in Q2 2021.
- The 5-year median for Income from Continuing Operations is 18234025.0 (2023), against an average of 20149797.37.
- Across the five-year window, Income from Continuing Operations soared 117.27% in 2024 and slumped 819.05% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 10433727.0 in 2021, then decreased by 1.34% to 10573403.0 in 2022, then retreated by 1.43% to 10725000.0 in 2023, then surged by 117.27% to 1852000.0 in 2024, then plunged by 1418.41% to 24417000.0 in 2025.
- Per Business Quant, the three latest CRBP Income from Continuing Operations figures stand at 24417000.0 (Q3 2025), 1314000.0 (Q2 2025), and 1359000.0 (Q1 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Corbus Pharmaceuticals Holdings | 164.14 Mn | 136.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -24.42 Mn |
| Jun 30, 2025 | 1.31 Mn |
| Mar 31, 2025 | -1.36 Mn |
| Dec 31, 2024 | 1.85 Mn |
| Sep 30, 2024 | -18.11 Mn |
| Jun 30, 2024 | -23.16 Mn |
| Mar 31, 2024 | 189,000.00 |
| Dec 31, 2023 | -10.73 Mn |
| Sep 30, 2023 | -30.31 Mn |
| Jun 30, 2023 | -28.96 Mn |
| Mar 31, 2023 | -18.23 Mn |
| Dec 31, 2022 | -10.57 Mn |
| Sep 30, 2022 | -19.16 Mn |
| Jun 30, 2022 | -23.16 Mn |
| Mar 31, 2022 | -9.20 Mn |
| Dec 31, 2021 | -10.43 Mn |
| Sep 30, 2021 | -52.68 Mn |
| Jun 30, 2021 | -53.96 Mn |
| Mar 31, 2021 | -51.75 Mn |
| Dec 31, 2020 | -20.98 Mn |